Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer : a phase II study of the European organization for research and treatment of cancer (EORTC 08984)

Biesma, B.; Manegold, C.; Smit, H.J.M.; Willems, L.; Legrand, C.; Passioukov, A.; van Meerbeeck, J.P.; Giaccone, G.

doi:10.1016/J.EJCA.2006.01.049

Title

Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer : a phase II study of the European organization for research and treatment of cancer (EORTC 08984)

Author

Biesma, B.

Manegold, C.

Smit, H.J.M.

Willems, L.

Legrand, C.

Passioukov, A.

van Meerbeeck, J.P.

Giaccone, G.

Institution/Organisation

EORTC Lung Cancer Group

Abstract

The objective of this phase II study was to document activity and toxicity of docetaxel and cisplatin as induction chemotherapy in patients with stage IIIA N2 non-small cell lung cancer (NSCLC) before definitive local treatment. Forty-six chemotherapy-naive patients (median age 60 years) were included. Treatment consisted of 3 cycles of docetaxel (85 mg/m(2) on day 1), followed by cisplatin (40 mg/m(2)/day on days 1 and 2) every 21 days. Grade 3-4 leukopenia and neutropenia occurred in 45.7% and 65.2% of the patients, respectively. Among 8 cases of febrile neutropenia (17.4%), one (2.2%) resulted in early death. Common grade 3-4 non-haematological toxicities were nausea (17.4%) and vomiting (13%). Eighty-five percent of the patients received three courses; six stopped prematurely due to toxicity, one due to protocol violation. Response rate was the primary endpoint of this study. Considering eligible patients (n = 40), 18 responses (1 complete and 17 partial responses) were observed (response rate 45%; 95% Confidence interval (CI): 29.3%-61.5%). In stage IIIA-N2 NSCLC patients, docetaxel-cisplatin could be administered and demonstrated manageable toxicity with modest efficacy. (c) 2006 Elsevier Ltd. All rights reserved.

Language

English

Source (journal)

European journal of cancer. - Oxford, 1990, currens

Publication

Oxford : 2006

ISSN

0959-8049 [print]

1879-0852 [online]

DOI

10.1016/J.EJCA.2006.01.049

Volume/pages